Industry
Biotechnology
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Loading...
Open
51.98
Mkt cap
3.1B
Volume
401K
High
51.98
P/E Ratio
-38.45
52-wk high
64.98
Low
48.30
Div yield
N/A
52-wk low
37.55
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 10:24 am
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 12:23 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 10:27 am
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 9:55 am
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 5:18 pm
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 10:31 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 10:22 am
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 12:41 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 10:41 am
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 9:48 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.